KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib

William Pao; Theresa Y Wang; Gregory J Riely; Vincent A Miller; Qiulu Pan; Marc Ladanyi; Maureen F Zakowski; Robert T Heelan; Mark G Kris; Harold E Varmus

doi:10.1371/journal.pmed.0020017

Loading metrics

Open Access

Peer-reviewed

Research Article

KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib

William Pao ,

*To whom correspondence should be addressed. E-mail: paow@mskcc.org

Affiliations Program in Cancer Biology and Genetics, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America
⨯
Theresa Y Wang,

Affiliation Program in Cancer Biology and Genetics, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America
⨯
Gregory J Riely,

Affiliation Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America
⨯
Vincent A Miller,

Affiliation Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America
⨯
Qiulu Pan,

Affiliation Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America
⨯
Marc Ladanyi,

Affiliation Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America
⨯
Maureen F Zakowski,

Affiliation Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America
⨯
Robert T Heelan,

Affiliation Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America
⨯
Mark G Kris,

Affiliation Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America
⨯
Harold E Varmus

Affiliation Program in Cancer Biology and Genetics, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America
⨯

KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib

William Pao,
Theresa Y Wang,
Gregory J Riely,
Vincent A Miller,
Qiulu Pan,
Marc Ladanyi,
Maureen F Zakowski,
Robert T Heelan,
Mark G Kris,
Harold E Varmus

Published: January 25, 2005
https://doi.org/10.1371/journal.pmed.0020017

Reader Comments (0)

Post a new comment on this article

Subject Areas
?

For more information about PLOS Subject Areas, click here.
We want your feedback. Do these Subject Areas make sense for this article? Click the target next to the incorrect Subject Area and let us know. Thanks for your help!

Lung and intrathoracic tumors
Is the Subject Area "Lung and intrathoracic tumors" applicable to this article?

Thanks for your feedback.
Non-small cell lung cancer
Is the Subject Area "Non-small cell lung cancer" applicable to this article?

Thanks for your feedback.
Mutation
Is the Subject Area "Mutation" applicable to this article?

Thanks for your feedback.
Cancer treatment
Is the Subject Area "Cancer treatment" applicable to this article?

Thanks for your feedback.
Adenocarcinoma of the lung
Is the Subject Area "Adenocarcinoma of the lung" applicable to this article?

Thanks for your feedback.
Adenocarcinoma
Is the Subject Area "Adenocarcinoma" applicable to this article?

Thanks for your feedback.
Kinase inhibitors
Is the Subject Area "Kinase inhibitors" applicable to this article?

Thanks for your feedback.
Secondary lung tumors
Is the Subject Area "Secondary lung tumors" applicable to this article?

Thanks for your feedback.